Cohance Lifesciences News

Compliance Certificate under reg. 74(5) of SEBI (DP) Regulations

Newspaper Publication

Markets have an element of probability. The way things have panned out in the last few weeks, it is likely the bulls will strengthen their case for a sustained comeback. Mind you, we are using the word “sustained”. A caveat, though: President Trump should not fire a fresh salvo. Also, keep in mind that corrections will happen as they are a part of the market. But, at this point of time, it is more important to look at how the fundamentals of a sector are shaping up. While everyone is focused on the GST effect, don’t forget that many sectors are being impacted by the tariffs. So, in the euphoria over GST, don’t forget that the fundamentals of a sector are different from tax rates.

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSCGlobal Capital Markets (Singapore) Pte. Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2025 for Jusmiral Holdings Ltd

Scrutinizer`s report for 7th Annual General Meeting

Outcome of the 7th Annual General Meeting.

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jusmiral Holdings Ltd & PACs

Clarification on reported news in electronic media

Investor meet

Indian markets ended higher Thursday as Sensex rose 320 points and Nifty 93, marking a third straight gain. Fed’s 25 bps rate cut, GST reforms, and trade progress boosted investor sentiment.

Disclosure under SEBI PIT Regulations

Investors Meet

Jefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Sciences, and Piramal Pharma for gains up to 30%, while flagging Laurus Labs as underperforming.

Completion of USFDA Inspection

Investors Meet

Letter to shareholders regarding Annual Report

Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015

News Paper Publication

Investors Meet

Credit Rating

BRSR 2025

Annual Report for FY 2024-25

Notice of 7th Annual General Meeting to be held on September 19, 2025

Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing strong growth prospects in India’s CRDMO sector. The brokerage sees a high-teen revenue CAGR, led by China+1 diversification, pipeline visibility, and demand for diabetes and weight-loss therapies.

Earnings Call Transcript

Investor meet

Newspaper Publication

Completion of USFDA Inspection

Concall Audio Link

Outcome of the Board Meeting

Outcome of the Board Meeting

Press Release

Press Release

Giving of Corporate Guarantee

When the Nifty and Sensex are rising every other day in tandem with bullish headlines, it is difficult to think rationally about valuations. Similarly, when they are falling every second day, it is difficult to think about what business you will own when you buy a stock, and that corrections are part markets, and that they will keep happening. And that, in the end, it is all about earnings.

Press Release

Change in management

Schedule of Conference Call for Investors and analysts

Schedule of Conference Call for Investors and analysts